Search clinical trials for: Multiple Risk Factors Interventional Strategies

Total 57138 results

Ministry of Health, Malaysia

Completed

Community Based Multiple Risk Factors Intervention Strategy (CORFIS)

Hypertension | Diabetes Mellitus | Hyperlipidemia

Malaysia
National Cancer Institute (NCI)

Recruiting

Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

United States
Wuhan Union Hospital, China

Recruiting

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Multiple Myeloma | Extramedullary Multiple Myeloma | Primary Plasma Cell Leukemia

China
Karolinska Institutet

Completed

Evaluating the Effectiveness of Multifaceted Implementation Strategies for Implementing a Guideline for the Prevention of Common Mental Disorders at the Workplace in Schools

Common Mental Disorders

Sweden
Eisai Inc.
Thrombolysis In Myocardial Infarction (TIMI) Academic Research Organization

Completed

A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors (CAMELLIA-TIMI)

Obesity | Cardiovascular Disease | Overweight | Type 2 Diabetes | High Cardiovascular Risk

United States, Canada, Poland, Australia, Mexico, New Zealand, Bahamas, Chile
The First Affiliated Hospital of Soochow University

Not yet recruiting

Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

Multiple Myeloma | Newly Diagnosed | MRD | High Risk
M.D. Anderson Cancer Center

Not yet recruiting

Endometrial Cancer, Risk Factors and Prevention Strategies: Perspectives of Patients and At-Risk Women

Endometrial Cancer

United States
Eli Lilly and Company

Recruiting

The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Renal Function in Adults Living With Obesity (TRIUMPH-OUTCOMES)

Overweight and Obesity

United States, Australia, Italy, Hungary, Spain, Canada, Germany, Argentina, Belgium, Czechia, Greece, Israel, Austria, Brazil, Mexico, Netherlands, Romania, India, United Kingdom, Slovakia, Poland, Turkey, Puerto Rico, France, Denmark
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Risk Stratification and New Early Prevention and Treatment Strategies for Patients With Cardiomyopathy (STRENGTH）

Cardiomyopathies

China
First Affiliated Hospital Xi'an Jiaotong University

Not yet recruiting

Risk Stratification, Early Prevention and Treatment Strategies for Arrhythmogenic Cardiomyopathy (STARTER)

Arrhythmogenic Cardiomyopathy

China
Insel Gruppe AG, University Hospital Bern

Not yet recruiting

CT-guided Lung Biopsy Risk Optimization Method (BROM-I)

Pneumothorax | Risk Factors | Biopsy, Needle | Radiology, Interventional

Switzerland
Maastricht University Medical Center

Recruiting

Real-world Evaluation of Diagnostic and Treatment Strategies in Low-Risk Basal Cell Carcinoma (REDT-BCC)

Basal Cell Carcinoma

Netherlands
M.D. Anderson Cancer Center
Pfizer

Not yet recruiting

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Multiple Myeloma | Post-transplant MRD-guided Maintenance Therapy | Pre-transplant Purging

United States
Stichting Hemato-Oncologie voor Volwassenen Nederland

Not yet recruiting

FeAsiBility of a Treatment Free Interval in Newly Diagnosed MM Patients Treated With Daratumumab-lenalidomide-dexamethasone (HOVON174MM) (HOVON174MM)

Multiple Myeloma
Assiut University

Not yet recruiting

Acute Kidney Injury in Pediatric Polytrauma Patients at Assiut University Trauma Unit: A Cross-Sectional Study on Incidence and Predictive Risk Factors

Acute Kidney Injury
University of California, San Francisco
American Society of Clinical Oncology; Conquer Cancer Foundation

Recruiting

PROmOting Gynecologic Cancer Patients With Frailty to Achieve Functional Recovery (PROOF)

Gynecologic Cancer | Malignant Female Reproductive System Neoplasm | Gynecologic Neoplasm

United States
Karolinska Institutet

Recruiting

Incidence of Acute Kidney Injury and Risk Factors in Newborns With Congenital Diaphragmatic Hernia

Acute Kidney Injury | Pulmonary Hypertension | Congenital Diaphragmatic Hernia | Multiple Organ Failure | Hyperchloremia

Sweden
Sixth Affiliated Hospital, Sun Yat-sen University

Recruiting

Safety and Efficacy of PD-1 ± mFOLFOX6 Neoadjuvant Therapy in Local Advanced sMPCC

Colorectal Cancer | Multiple Cancer

China
Eli Lilly and Company

Recruiting

A Master Protocol (LY900023) That Includes Several Clinical Trials of Drugs for Children and Young Adults With Cancer (CAMPFIRE)

Adolescent | Neoplasms | Child

United States, Spain, United Kingdom, Australia, Italy, Japan, Belgium, France, Germany
Lebanese University
Hospital Saydet Zgharta University Medical Center

Recruiting

LUSZ Treatment Efficacy in Hospitalized COVID-19 Patients (LUSZ_AVIST)

COVID-19 | Hospitalized COVID-19 Patients

Lebanon
PETHEMA Foundation
Janssen Pharmaceutica

Recruiting

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma (GEM-TECTAL)

High-Risk de Novo Multiple Myeloma

Spain
M.D. Anderson Cancer Center
Sanofi

Recruiting

Post-Transplant Maintenance Therapy With Isatuximab Plus Lenalidomide for High-Risk Multiple Myeloma Patients

Multiple Myeloma

United States
Second Affiliated Hospital, School of Medicine,...
Shaoxing People's Hospital; Shaoxing Second Hospital; Huizhou Municipal Central... and other collaborators

Recruiting

Ixazomib Plus Low-dose Lenalidomide Versus Ixazomib Alone for Maintenance Treatment of High Risk Multiple Myeloma

Multiple Myeloma

China
GlaxoSmithKline

Recruiting

A Study to Investigate the Safety and Efficacy of Belantamab for the Treatment of Multiple Myeloma When Used as Monotherapy and in Combination Treatments (DREAMM-20)

Multiple Myeloma

Australia, Poland, Taiwan, Korea, Republic of, Japan, United Kingdom, Brazil, Mexico, Turkey, Argentina
EDUARDO ALBENIZ
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Spain; Fundació... and other collaborators

Recruiting

The EpiGASTRIC/EDGAR Project: New Strategies for the Early Detection and Prevention of Gastric Cancer

Gastric Cancer | Gastric Neoplasms | Gastric Lesion

Spain
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

Combination Treatment Therapy Approaches for the Treatment of High-Risk Multiple Myeloma, REACH Trial

Plasma Cell Myeloma | ISS Stage III Plasma Cell Myeloma

United States
Irene Ghobrial, MD
Janssen Research & Development, LLC

Recruiting

Immuno-PRISM (PRecision Intervention Smoldering Myeloma)

Multiple Myeloma | Smoldering Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
Xia Zhongjun
Antengene Corporation

Recruiting

Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

Multiple Myeloma

China
National Cancer Institute (NCI)

Recruiting

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Hematologic Neoplasms

United States
Emory University
National Cancer Institute (NCI); GlaxoSmithKline

Recruiting

Belantamab Mafodotin, Pomalidomide and Dexamethasone for the Treatment of High-Risk Myeloma

Plasma Cell Myeloma

United States
Assiut University

Recruiting

Cardiovascular Risk Factors , Complications and Threputic Management Strategies in Patients With Coronary Heart Disease and COVID 19

Ischemic Heart Disease

Egypt
Verity Pharmaceuticals Inc.

Not yet recruiting

Evaluating Safety and Efficacy of Verity-BCG in BCG-naïve Patients With Intermediate and High-risk Non-muscle Invasive Bladder (NMIBC) (EVER)

Bladder Cancer | Urothelial Carcinoma Bladder | Bladder Cancer Recurrent | Neoplasm Recurrence | Urothelial Carcinoma Recurrent | Non-Invasive Bladder Urothelial Carcinoma
City of Hope Medical Center
National Cancer Institute (NCI)

Recruiting

Leflunomide for the Treatment of High-Risk Smoldering Multiple Myeloma in African-American and European-American Patients

Smoldering Plasma Cell Myeloma

United States
World Health Organization
University of Bern; University of Wollongong; Fondation Botnar

Recruiting

Empowering Adolescents to Lead Change Using Health Data

Healthy

Ghana, India, Jamaica, Morocco, Switzerland
Fu Jen Catholic University

Recruiting

Vegan Diet, Amla Fruits and Uric Acid

Hyperuricemia | Diet, Healthy | Cardiometabolic Syndrome

Taiwan
Omar Nadeem, MD
Janssen, LP

Recruiting

DARA RVD For High Risk SMM (PRISM)

Multiple Myeloma | High-risk Smoldering Multiple Myeloma

United States
McGill University Health Centre/Research Institute...

Not yet recruiting

Incidence and Associated Risk Factors of ARC in the Trauma Critically Ill Older Than 50 Years Old

Critical Illness | Traumatic Brain Injury | Polytrauma | Augmented Renal Clearance

Canada
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Not yet recruiting

²¹¹At-OKT10-B10 and Fludarabine Alone or in Combination With Cyclophosphamide and Low-Dose TBI Before Donor Stem Cell Transplant for the Treatment of Newly Diagnosed, Recurrent, or Refractory High-Risk Multiple Myeloma

Plasma Cell Myeloma | Refractory Plasma Cell Myeloma | Recurrent Plasma Cell Myeloma

United States
Sanofi

Recruiting

A Prospective, Non-interventional, Multinational, Observational Study With Isatuximab in Patients With Relapsed and/or Refractory Multiple Myeloma (RRMM) (IONA-MM)

Plasma Cell Myeloma

Germany, United States, Argentina, China, France, Hong Kong, Italy, Japan, Puerto Rico, Spain, Switzerland, United Arab Emirates, United Kingdom, Austria, Belgium, Netherlands, Taiwan
The University of Hong Kong

Recruiting

Cohort Study on Patient Outcomes, Effectiveness and Cost-effectiveness of Intervention Programmes for DM/HT Patients (TRACC)

Cardiovascular Diseases | Hypertension | Diabetes Mellitus | Death | Kidney Disease, Chronic | Morbidity, Multiple

China
CellCentric Ltd.

Recruiting

Study to Evaluate CCS1477 in Haematological Malignancies

Acute Myeloid Leukemia | Multiple Myeloma | Non Hodgkin Lymphoma | Peripheral T Cell Lymphoma | Haematological Malignancy | Higher-risk Myelodysplastic Syndrome

United Kingdom, United States, France, Sweden, Spain
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Recruiting

Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma

Smoldering Plasma Cell Myeloma

United States
Institut Jerome Lejeune

Recruiting

Cohort Study of Adult Patients With Down Syndrome at Risk of Developing Alzheimer's Disease (TriAL21)

Alzheimer Disease | Down Syndrome

France
University Hospital, Toulouse

Recruiting

Study Association of Lenalidomide, Ixazomib, Dexamethasone and Daratumumab in Newly Diagnosed Standard Risk Multiple Myeloma (IFM2018-01)

Multiple Myeloma

France
Sun Yat-sen University

Recruiting

VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

Myeloma | Newly Diagnosed | High Risk

China
University of Colorado, Denver
Colorado School of Public Health

Recruiting

Risk Factors in Early Multiple Sclerosis (RISEMS)

Multiple Sclerosis | Clinically Isolated Syndrome | Biomarkers | Magnetic Resonance Imaging | Radiologically Isolated Syndrome

United States
National Cancer Institute (NCI)

Active, not recruiting

Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma

Smoldering Multiple Myeloma | Light Chain Deposition Disease

United States, Puerto Rico, Ireland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies

Metastatic Renal Cell Carcinoma | Metastatic Lung Non-Small Cell Carcinoma | Stage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Metastatic Melanoma | Fallopian Tube Carcinoma | Advanced Malignant Solid Neoplasm | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage III Renal... and other conditions

United States
Hoffmann-La Roche

Active, not recruiting

Non-interventional Study of Ocrelizumab in Participants With Relapsing or Primary Progressive Multiple Sclerosis (MuSicalE)

Multiple Sclerosis

Belgium, United Kingdom, Netherlands, Serbia, Poland, Slovakia, Bulgaria, Turkey, Brazil, Italy, Russian Federation, Spain, Austria, Colombia, Romania, Kuwait, Chile, Dominican Republic, Egypt, Montenegro, Panama, Paraguay, Portugal, ... and more
Gustave Roussy, Cancer Campus, Grand Paris
National Cancer Institute, France

Terminated

Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction (VERITAS)

Very High Risk Neuroblastoma

Italy, Austria, France, Netherlands, Spain

Search clinical trials for: Multiple Risk Factors Interventional Strategies

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kuwait

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations